- Minaris has upgraded its Viral Clearance laboratory at its Philadelphia campus, expanding capacity to four client suites.
- The upgrade is expected to increase laboratory throughput by approximately 25% and support flexible study configurations for biosafety testing clients.
Minaris has announced an upgrade to its Viral Clearance laboratory capabilities at its Philadelphia campus, expanding capacity to four new client suites. The investment supports Minaris Advanced Testing, the company’s business unit providing multimodality biosafety testing services to U.S. and global clients.
The upgraded facility is designed to improve operational efficiency through a new laboratory layout, optimized workflows, and the use of advanced digital tools. Minaris said the expansion is expected to increase laboratory throughput by approximately 25% and enable more flexible study configurations to support timelines, cost efficiency, and quality across a range of therapeutic platforms.
The enhanced Viral Clearance capabilities also increase capacity for Validation on Demand services, allowing sponsors to conduct Viral Clearance studies using Minaris’ trained scientists. The services are intended to support both innovative and established programs requiring biosafety testing as part of development and regulatory submissions.
“This investment reflects our long-term commitment to the Philadelphia campus as a center of excellence for biosafety testing and is an integral part of our end-to-end services platform.”
Orla Cloak, Chief Executive Officer of Minaris
The Viral Clearance upgrade forms part of Minaris’ broader Philadelphia site growth strategy, supporting closer integration between biosafety testing and the company’s development and manufacturing operations.
